Bristol-Myers Squibb (NYSE: BMY)
You’re reading a free stock page from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Bristol-Myers Squibb Returns vs. S&P
|1 Year||5 Year||5 Year Annualized||Since IPO|
Bristol-Myers Squibb Company Info
Bristol-Myers Squibb discovers, develops, licenses, makes, and sells pharmaceuticals, with particular success in cardiovascular treatments.
News & Analysis
These titans of big pharma just enrolled patients into phase 3 clinical trials for this promising blood thinner.
Learn about some of the leading cancer stocks in the U.S stock market this year.
Both companies have outperformed the market over the past year.
These are blue chip stocks you can hold in your portfolio for many years.
This drugmaker is one of the most well-known in the world.
Biotech stocks aren't all created equal -- these two are the best of the bunch.
Bristol Myers' Sotyktu recently moved one step closer to its first approval in the European Union.
These companies are established leaders in their respective fields.
The potential to reshape treatment of blood cancer and disorders could mean big bucks for these companies.
These stocks skyrocketed following exciting announcements.
Carl Icahn's reportedly focusing his brand of investor activism on Bristol-Myers Squibb, but it's anyone's guess if he'll be able to convince the company to sell. Also, Celgene delivers a phase 3 win with blockbuster implications.
In this Valentine's Day edition, Industry Focus explores cholesterol busters, heart surgery, and the latest in anticoagulants.
BMY earnings call for the period ending December 31, 2022.
BMY earnings call for the period ending September 30, 2022.
BMY earnings call for the period ending June 30, 2022.
BMY earnings call for the period ending March 31, 2022.
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.